Autopsy report · NCT06780033

A Study to Evaluate ART101 in Adult Participants With Hypertension

“At Sponsor's Request”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 month before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Arnatar Therapeutics, Inc.

Sponsor type

Industry

Conditions

Hypertension

Interventions

ART-101 - SAD; Placebo

Participants

1

Sites

3

Countries

Australia

Trials that died the same way

• A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer
  “requested by sponsor” (87% match in meaning)
• Effects of Metreleptin in Type 1 Diabetes Mellitus
  “Sponsor request” (86% match in meaning)
• OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
  “Due to sponsor request” (82% match in meaning)
• Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
  “For interests of sponsor.” (73% match in meaning)
• Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed
  “Sponsor related” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.